Show simple item record

dc.contributor.authorDjurec, Magdolna
dc.contributor.authorGraña Castro, Osvaldo 
dc.contributor.authorLee, Albert
dc.contributor.authorTroulé, Kevin
dc.contributor.authorEspinet, Elisa
dc.contributor.authorCabras, Lavinia
dc.contributor.authorNavas, Carolina
dc.contributor.authorBlasco, María Teresa
dc.contributor.authorMartín-Díaz, Laura
dc.contributor.authorBurdiel, Miranda
dc.contributor.authorLi, Jing
dc.contributor.authorLiu, Zhaoqi
dc.contributor.authorVallespinós, Mireia
dc.contributor.authorSanchez-Bueno, Francisco
dc.contributor.authorSprick, Martin R
dc.contributor.authorTrumpp, Andreas
dc.contributor.authorSainz, Bruno
dc.contributor.authorAl-Shahrour, Fatima 
dc.contributor.authorRabadan, Raul
dc.contributor.authorGuerra, Carmen 
dc.contributor.authorBarbacid, Mariano 
dc.date.accessioned2019-08-20T06:04:16Z
dc.date.available2019-08-20T06:04:16Z
dc.date.issued2018-02-06
dc.identifier.citationProc Natl Acad Sci U S A. 2018 ;115(6):E1147-E1156.es_ES
dc.identifier.issn0027-8424es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8305
dc.description.abstractPancreatic ductal adenocarcinoma (PDAC) is characterized by the presence of abundant desmoplastic stroma primarily composed of cancer-associated fibroblasts (CAFs). It is generally accepted that CAFs stimulate tumor progression and might be implicated in drug resistance and immunosuppression. Here, we have compared the transcriptional profile of PDGFRα+ CAFs isolated from genetically engineered mouse PDAC tumors with that of normal pancreatic fibroblasts to identify genes potentially implicated in their protumorigenic properties. We report that the most differentially expressed gene, Saa3, a member of the serum amyloid A (SAA) apolipoprotein family, is a key mediator of the protumorigenic activity of PDGFRα+ CAFs. Whereas Saa3-competent CAFs stimulate the growth of tumor cells in an orthotopic model, Saa3-null CAFs inhibit tumor growth. Saa3 also plays a role in the cross talk between CAFs and tumor cells. Ablation of Saa3 in pancreatic tumor cells makes them insensitive to the inhibitory effect of Saa3-null CAFs. As a consequence, germline ablation of Saa3 does not prevent PDAC development in mice. The protumorigenic activity of Saa3 in CAFs is mediated by Mpp6, a member of the palmitoylated membrane protein subfamily of the peripheral membrane-associated guanylate kinases (MAGUK). Finally, we interrogated whether these observations could be translated to a human scenario. Indeed, SAA1, the ortholog of murine Saa3, is overexpressed in human CAFs. Moreover, high levels of SAA1 in the stromal component correlate with worse survival. These findings support the concept that selective inhibition of SAA1 in CAFs may provide potential therapeutic benefit to PDAC patients.es_ES
dc.description.sponsorshipWe thank Beatriz Jiménez, María del Carmen G. Lechuga, Marta San Roman, Raquel Villar, and Silvia Jiménez for excellent technical assistance; Jaime Muñoz and Sagrario Ortega (CNIO Transgenic Unit) for help in generating Saa3-null mice; Isabel Aragón, Mayte Lamparero, Alejandra López, Patricia Villanueva, and Isabel Blanco (CNIO Animal Facility)for mouse work; Gloria Visdomine, Cristina Peñalba, and Francisca Mulero (CNIO Molecular Imaging Unit) for ultrasound studies; Manuel Pérez, Jesús Gómez, and Diego Megías (CNIO Confocal Microscopy Unit) for confocal im-aging; Ultan Cronin and LolaMartínez (Flow Cytometry Unit) for FACS analysis; Nuria Cabrera and Alba de Martino (Histopathology Unit) for histopatholog-ical analysis; Manuel Morente for his advice with immunohistochemical (CNIO Tumor Bank); Corinna Klein for advice concerning the orthotopic studies; and the German Cancer Research Center-Heidelberg Center for Personalized Oncology (DKFZ-HIPO) for technical support and funding through the Grant HIPO-015. This work was supported by European Research CouncilGrants ERC-AG/250297-RAS AHEAD and ERC-AG/695566-THERACAN, Spanish Ministry of Economy and Competiti veness Grant SAF2014-59864-R, andAsociación Española contra el Cáncer Grant GC16173694BARB (to M. Barbacid).M.D. was supported by a fellowship from La Caixa International Fellowship Program. M. Barbacid is the recipient of an Endowed Chair from the AXA Research Fund.es_ES
dc.language.isoenges_ES
dc.publisherNATL ACAD SCIENCESes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectCAFses_ES
dc.subjectPDACes_ES
dc.subjectSaa3es_ES
dc.subjectmouse modelses_ES
dc.subjectstromaes_ES
dc.subject.meshAnimals es_ES
dc.subject.meshCancer-Associated Fibroblasts es_ES
dc.subject.meshCarcinoma, Pancreatic Ductal es_ES
dc.subject.meshCell Movement es_ES
dc.subject.meshCell Proliferation es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHigh-Throughput Nucleotide Sequencing es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMice es_ES
dc.subject.meshMice, Inbred C57BL es_ES
dc.subject.meshMice, Knockout es_ES
dc.subject.meshPancreas es_ES
dc.subject.meshPancreatic Neoplasms es_ES
dc.subject.meshSerum Amyloid A Protein es_ES
dc.subject.meshStromal Cells es_ES
dc.subject.meshTumor Microenvironment es_ES
dc.titleSaa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumorses_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID29351990es_ES
dc.format.volume115es_ES
dc.format.number6es_ES
dc.format.pageE1147-E1156es_ES
dc.identifier.doi10.1073/pnas.1717802115es_ES
dc.contributor.funderGerman Cancer Research Center-Heidelberg Center for Personalized Oncology (DKFZ-HIPO)es_ES
dc.contributor.funderEuropean Research Counciles_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderAsociación Española Contra el Cánceres_ES
dc.contributor.funderFundación La Caixaes_ES
dc.contributor.funderAXA Research Fundes_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1091-6490es_ES
dc.relation.publisherversionhttps://doi.org/10.1073/pnas.1717802115es_ES
dc.identifier.journalProceedings of the National Academy of Sciences of the United States of Americaes_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Oncología Experimentales_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/250297es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/695566es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2014-59864-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/GC16173694BARBes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional